4basebio Plc - Director Dealing
News provided by
4basebio Plc16 Feb, 2026, 07:00 GMT
16 February 2026
4basebio PLC
("4basebio" or the "Company")
Director Dealing
Cambridge, UK, 16 February 2026 – 4basebio PLC (AIM: 4BB), an innovation driven biotechnology company enabling and accelerating development of advanced therapy medicinal products (ATMPs) through its high performant GMP-grade synthetic DNA products, announces that on 13 February 2026 it was informed that Dr. Amy Walker, Chief Executive Officer of the Company made the following purchase in ordinary shares in the capital of the Company through the market.
Further details are set out in the Notification of Dealing Form below.
| Director / PCA | Number of Ordinary Shares Acquired | Purchase Price (Aggregated) (p) | Shareholding Following Acquisition | Shareholding Following Acquisition as a Percentage of Issued Share Capital |
| Dr. Amy Walker | 2,650 | 586.08 | 46,666 | 0.30% |
The 2,650 shares purchased represent approximately 0.02 per cent. of the Company's issued share capital.
The issued share capital of the Company comprises 15,538,518 ordinary shares.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 as amended by regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310.
For further enquiries, please contact:
| 4basebio PLC | +44 (0)12 2396 7943 |
| Dr Amy Walker, CEO | |
| Cairn Financial Advisers LLP (Nominated Adviser ) | +44 (0)20 7213 0880 |
| Jo Turner / Sandy Jamieson / Ed Downes | |
| Cavendish Capital Markets Limited (Joint Broker) | +44 (0)20 7220 0500 |
| Geoff Nash / Nigel Birks | |
| RBC Capital Markets (Joint Broker) | +44 (0)20 7653 4000 |
| Kathryn Deegan / Matthew Coakes ICR Healthcare (Media and Investor Relations) Mary-Jane Elliott / Jessica Hodgson |
+44 (0)203 707 5700 |
Notes to Editors
About 4basebio
4basebio (AIM: 4BB) is an innovation driven life biotechnology company focused on accelerating the development of advanced therapy medicinal products (ATMPs) through its high-performance synthetic DNA products and non-viral, cell targeting nucleic acid delivery platform. The Company’s objective is to become a market leader in the manufacture and supply of high-quality synthetic DNA products for research, therapeutic and pharmacological use as well as development of target specific non-viral vectors for the efficient delivery of payloads in patients.
Forward-looking statements
This announcement may contain certain statements about the future outlook for 4basebio. Although the directors believe their expectations are based on reasonable assumptions, any statements about future outlook may be influenced by factors that could cause actual outcomes and results to be materially different.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
| 1 | Details of the persons discharging managerial responsibilities / person closely associated | |||||||
| a) | Name | Dr. Amy Walker | ||||||
| 2 | Reason for the notification | |||||||
| a) | Position/Status | Chief Executive Officer | ||||||
| b) | Initial notification/ Amendment | Initial notification | ||||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||
| a) | Name | 4basebio plc | ||||||
| b) | LEI | 213800E2DX9EAIUNCB30 | ||||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares ISIN: GB00BMCLYF79 |
||||||
| b) | Nature of the transaction | Acquisition of ordinary shares | ||||||
| c) | Price(s) and volume(s) |
|
||||||
| d) | Aggregated information - Aggregated volume - Aggregated Price | 2,650 586.08p | ||||||
| e) | Date of transaction | 13 February 2026 | ||||||
| f) | Place of transaction | London Stock Exchange | ||||||
The content and accuracy of news releases published on this site and/or distributed by PR Newswire or its partners are the sole responsibility of the originating company or organisation. Whilst every effort is made to ensure the accuracy of our services, such releases are not actively monitored or reviewed by PR Newswire or its partners and under no circumstances shall PR Newswire or its partners be liable for any loss or damage resulting from the use of such information. All information should be checked prior to publication.
